1. Home
  2. BCDA vs IHT Comparison

BCDA vs IHT Comparison

Compare BCDA & IHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$0.93

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Logo InnSuites Hospitality Trust Shares of Beneficial Interest

IHT

InnSuites Hospitality Trust Shares of Beneficial Interest

HOLD

Current Price

$1.56

Market Cap

15.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCDA
IHT
Founded
N/A
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
15.2M
IPO Year
2009
1995

Fundamental Metrics

Financial Performance
Metric
BCDA
IHT
Price
$0.93
$1.56
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
280.9K
17.3K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
1.77%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$479,000.00
$7,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.33
52 Week Low
$0.75
$0.95
52 Week High
$2.29
$4.24

Technical Indicators

Market Signals
Indicator
BCDA
IHT
Relative Strength Index (RSI) 51.82 49.73
Support Level $0.79 $1.01
Resistance Level $1.29 $1.86
Average True Range (ATR) 0.07 0.11
MACD 0.02 -0.01
Stochastic Oscillator 75.69 46.46

Price Performance

Historical Comparison
BCDA
IHT

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About IHT InnSuites Hospitality Trust Shares of Beneficial Interest

InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.

Share on Social Networks: